Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.
Lava Therapeutics, a Netherlands-based immuno-oncology therapy spinout of Amsterdam University Medical Centers (Amsterdam UMC), secured $83m yesterday in a series C round.
The round was co-led by Novo Ventures and Sanofi Ventures, investment vehicles for pharmaceutical firms Novo and Sanofi respectively.
MRL Ventures Fund, a subsidiary of pharmaceutical firm Merck & Co’s Merck Research Laboratories division, also took part in the round, which additionally included Redmile Group, Ysios Capital, BB Pureos Bioventures, Versant Ventures and Gilde Healthcare.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
